Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Pharmacology and Therapeutics

Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway

  1. Cecilia Ratner1,2⇑,
  2. Zhenyan He3,
  3. Kaare V. Grunddal2,
  4. Louise J. Skov1,2,
  5. Bolette Hartmann1,2,
  6. Fa Zhang4,
  7. Annette Feuchtinger5,
  8. Anette Bjerregaard1,2,
  9. Christina Christoffersen2,6,
  10. Matthias H. Tschöp7,8,
  11. Brian Finan9,
  12. Richard D. DiMarchi4,
  13. Gina M. Leinninger10,
  14. Kevin W. Williams3,
  15. Christoffer Clemmensen1 and
  16. Birgitte Holst1,2
  1. 1Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark
  2. 2Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
  3. 3Division of Hypothalamic Research, Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX
  4. 4Department of Chemistry, Indiana University, Bloomington, IN
  5. 5Research Unit Analytical Pathology, Helmholtz Zentrum München, Munich, Germany
  6. 6Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark
  7. 7Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München, Munich, Germany
  8. 8Division of Metabolic Diseases, Department of Medicine, Technische Universität München, Munich, Germany
  9. 9Novo Nordisk Research Center Indianapolis, Indianapolis, IN
  10. 10Department of Physiology, Michigan State University, East Lansing, MI
  1. Corresponding author: Cecilia Ratner, cecilia.ratner{at}sund.ku.dk
Diabetes 2019 Jun; 68(6): 1329-1340. https://doi.org/10.2337/db18-1009
PreviousNext
  • Article
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 68 no. 6 1329-1340
DOI 
https://doi.org/10.2337/db18-1009
PubMed 
30936142

Published By 
American Diabetes Association
Print ISSN 
0012-1797
Online ISSN 
1939-327X
History 
  • Received September 18, 2018
  • Accepted March 18, 2019
  • Published in print May 20, 2019.
  • Published online ahead of print April 1, 2019.

Article Versions

  • Previous version (April 1, 2019 - 13:15).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2019 by the American Diabetes Association. http://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

Author Information

  1. Cecilia Ratner1,2⇑,
  2. Zhenyan He3,
  3. Kaare V. Grunddal2,
  4. Louise J. Skov1,2,
  5. Bolette Hartmann1,2,
  6. Fa Zhang4,
  7. Annette Feuchtinger5,
  8. Anette Bjerregaard1,2,
  9. Christina Christoffersen2,6,
  10. Matthias H. Tschöp7,8,
  11. Brian Finan9,
  12. Richard D. DiMarchi4,
  13. Gina M. Leinninger10,
  14. Kevin W. Williams3,
  15. Christoffer Clemmensen1 and
  16. Birgitte Holst1,2
  1. 1Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark
  2. 2Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
  3. 3Division of Hypothalamic Research, Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX
  4. 4Department of Chemistry, Indiana University, Bloomington, IN
  5. 5Research Unit Analytical Pathology, Helmholtz Zentrum München, Munich, Germany
  6. 6Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark
  7. 7Institute for Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Zentrum München, Munich, Germany
  8. 8Division of Metabolic Diseases, Department of Medicine, Technische Universität München, Munich, Germany
  9. 9Novo Nordisk Research Center Indianapolis, Indianapolis, IN
  10. 10Department of Physiology, Michigan State University, East Lansing, MI
  1. Corresponding author: Cecilia Ratner, cecilia.ratner{at}sund.ku.dk
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: March 2019 to April 2021

Rendering graph...
AbstractFullPdf
Mar 2019301
Apr 20197690185
May 20195126992
Jun 20193335546
Jul 20191652828
Aug 20191151916
Sep 20191192626
Oct 2019711816
Nov 2019482512
Dec 20191811629
Jan 20201417730
Feb 202071708
Mar 2020226514
Apr 2020217156
May 2020112938
Jun 202024020
Jul 202033812
Aug 202014924
Sep 202029157
Oct 202058235
Nov 202005633
Dec 202093920
Jan 202114725
Feb 202153923
Mar 202133516
Apr 2021067

PreviousNext
Back to top
Diabetes: 68 (6)

In this Issue

June 2019, 68(6)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway
Cecilia Ratner, Zhenyan He, Kaare V. Grunddal, Louise J. Skov, Bolette Hartmann, Fa Zhang, Annette Feuchtinger, Anette Bjerregaard, Christina Christoffersen, Matthias H. Tschöp, Brian Finan, Richard D. DiMarchi, Gina M. Leinninger, Kevin W. Williams, Christoffer Clemmensen, Birgitte Holst
Diabetes Jun 2019, 68 (6) 1329-1340; DOI: 10.2337/db18-1009

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway
Cecilia Ratner, Zhenyan He, Kaare V. Grunddal, Louise J. Skov, Bolette Hartmann, Fa Zhang, Annette Feuchtinger, Anette Bjerregaard, Christina Christoffersen, Matthias H. Tschöp, Brian Finan, Richard D. DiMarchi, Gina M. Leinninger, Kevin W. Williams, Christoffer Clemmensen, Birgitte Holst
Diabetes Jun 2019, 68 (6) 1329-1340; DOI: 10.2337/db18-1009
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Research Design and Methods
    • Results
    • Discussion
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial
  • Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench
  • Anti-Insulin Receptor Antibodies Improve Hyperglycemia in a Mouse Model of Human Insulin Receptoropathy
Show more Pharmacology and Therapeutics

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.